Inhibrx，股份有限公司宣布预计分拆的最新发行交易日期

圣地亚哥，2024年5月10日/PRNewswire/-Inhibrx，股份有限公司（纳斯达克股票代码：INBX）（“Inhibrix”或“公司”）今天宣布，鉴于公司之前宣布按比例向公司普通股持有人分配其子公司InhibrxBiosciences，股份有限公司（“SpinCo”）92%的普通股（“Spin-Off”），纳斯达克全球市场（“纳斯达克”）通知公司，纳斯达克打算允许在公司在将于2024年5月24日举行的公司特别股东大会上批准赛诺菲收购公司（“合并”）。

因此，SpinCo普通股股票预计将于2024年5月28日（而不是2024年的5月16日）在纳斯达克以“何时发行”为基础开始交易，以“INXB”和“Inhibrx Biosciences，股份有限公司”为符号。合并完成后，SpinCo的普通股将以“INBX”符号在纳斯达克上市，该符号目前是公司普通股的符号。

分拆的记录日期仍然是2024年5月17日，公司继续预计分拆中SpinCo普通股的股份分配将于美国东部时间2024年05月29日晚上11:59进行。此外，公司继续预计合并的截止日期将为2024年5月30日。分拆和合并的完成仍需遵守2024年4月26日提交的公司最终委托书中规定的交割条件，包括在2024年5月24日举行的公司特别股东大会上获得股东批准。

关于Inhibrx，股份有限公司。

Inhibrx是一家临床阶段的生物制药公司，专注于开发肿瘤学和孤儿疾病的新型候选生物治疗药物。Inhibrx利用多种蛋白质工程方法来满足复杂靶点和疾病生物学的特定要求，包括其专有的蛋白质工程平台。欲了解更多信息，请访问www.inhibrx.com。

关于赛诺菲

赛诺菲是一家创新的全球医疗保健公司，其宗旨只有一个：追逐科学奇迹，改善人们的生活。赛诺菲的团队遍布约100个国家，致力于通过将不可能变成可能来改变医学实践。赛诺菲为全球数百万人提供了可能改变生活的治疗选择和挽救生命的疫苗保护，同时将可持续性和社会责任置于其雄心的中心。

关于前瞻性声明的警示声明

This communication contains forward-looking statements about Sanofi's proposed acquisition of the Company and INBRX-101, and the Company's related spin-off of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109, its existing pipeline and corporate infrastructure, which involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by the Company's stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the integration of the Company and Sanofi will be more difficult, time consuming or costly than expected; risks and costs relating to the separation of the assets and liabilities associated with INBRX-105, INBRX-106 and INBRX-109 and the consummation of the spin-off in the anticipated timeframe or at all; changes to the configuration of the INBRX-105, INBRX-106 and INBRX-109 businesses included in the separation if implemented; disruption from the transaction making it more difficult to maintain business and operational relationships; risks related to diverting management's attention from the Company's ongoing business operation; negative effects of this announcement or the consummation of the proposed transaction on the market price of the Company's shares of common stock and/or operating results; significant transaction costs; risks associated with the discovery of unknown liabilities prior to or after the closing of the proposed transactions; the risk of litigation and/or regulatory actions related to the proposed transactions or the Company's business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; the conflicts in the Ukraine and the Middle East; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; and future business combinations or disposals. Important factors, risks and uncertainties that could cause actual results to differ materially from such forward looking statements also include but are not limited to the initiation, timing, progress and results of the Company's research and development programs as well as the Company's preclinical studies and clinical trials; the Company's ability to advance therapeutic candidates into, and successfully complete, clinical trials; the Company's interpretation of initial, interim or preliminary data from the Company's clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals, including whether any product candidate, receives approval from the FDA, or similar regulatory authority, for an accelerated approval process; the commercialization of the Company's therapeutic candidates, if approved; the pricing, coverage and reimbursement of the Company's therapeutic candidates, if approved; the Company's ability to utilize the Company's technology platform to generate and advance additional therapeutic candidates; the implementation of the Company's business model and strategic plans for the Company's business and therapeutic candidates; the Company's ability to successfully manufacture the Company's therapeutic candidates for clinical trials and commercial use, if approved; the Company's ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection the Company is able to establish and maintain for intellectual property rights covering the Company's therapeutic candidates; the Company's ability to enter into strategic partnerships and the potential benefits of such partnerships; the Company's estimates regarding expenses, capital requirements and needs for additional financing; the ability to raise funds needed to satisfy the Company's capital requirements, which may depend on financial, economic and market conditions and other factors, over which the Company may have no or limited control; the Company's financial performance; the Company's and the Company's third party partners' and service providers' ability to continue operations and advance the Company's therapeutic candidates through clinical trials and the ability of the Company's third party manufacturers to provide the required raw materials, antibodies and other biologics for the Company's preclinical research and clinical trials in light of current market conditions or any pandemics, regional conflicts, sanctions, labor conditions, geopolitical events, natural disasters or extreme weather events; the ability to retain the continued service of the Company's key professionals and to identify, hire and retain additional qualified professionals; and developments relating to the Company's competitors and the Company's industry; and other risks described from time to time in the "Risk Factors" section of its filings with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K as well as its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

附加信息和查找位置

本通信是与涉及公司、赛诺菲和合并协议其他各方的拟议交易有关的。公司于2024年4月26日提交了最终委托书，该委托书已邮寄给截至2024年3月24日与拟议收购有关的公司在册股东。本通信不能代替公司可能向美国证券交易委员会提交的委托书或任何其他文件。在做出任何投票决定之前，投资者和证券持有人应阅读与拟议收购有关的、向美国证券交易所提交或将提交的或通过引用纳入委托书的明确委托书和任何其他文件，因为这些文件将包含有关拟议收购的重要信息。对于拟在公司年度股东大会上提出的批准拟议收购的决议或与拟议收购有关的其他回应的任何投票，均应仅基于公司委托书中包含的信息进行。投资者和证券持有人可以在美国证券交易委员会网站www.SEC.gov或公司网站www.SEC.gov.上免费获得这些文件的副本（如有）和向美国证券交易会提交的其他相关文件https://www.inhibrx.com.

无要约或招揽

本通信仅供参考，不旨在也不构成要约、邀请或要约邀请的一部分，也不构成根据拟议交易或其他方式购买、以其他方式获取、认购、出售或以其他方式处置任何证券，或在任何司法管辖区内征求任何投票或批准，也不应在任何司法辖区内违反适用法律出售、发行或转让证券。

征集参与者

公司、其各自的董事和某些执行官可被视为“参与者”（定义见1934年《证券交易法》第14（a）条），就潜在交易向公司股东征求代理。关于公司（i）董事身份的信息载于2024年2月28日提交给美国证券交易委员会的公司10-K表年度报告第153页题为“我们的董事会”的部分（“2024 10-K”）（可在此处获取）；以及（ii）执行官的信息载列于2024 10-K表第157页题为《我们的执行官》的部分（可在这里获取）。关于公司非雇员董事薪酬的信息，请参见2024 10-K第158页题为“非雇员董事补偿政策”的章节（可在此处获取）。关于公司指定高管薪酬的信息，请参见2024 10-K第158页题为“高管薪酬”的章节（可在此处获取）。与关联人的交易（定义见1933年《证券法》颁布的S-K条例第404项）在2024 10-K第171页题为“某些关系和关联方交易”的章节中披露（可在此处查阅）。关于公司董事和指定高管对公司证券的实益所有权的信息，请参见最终委托书第118页标题为“某些实益所有人和管理层的证券所有权”的章节（可在此处查阅）。关于委托书征集中某些参与者的其他信息，以及通过证券持有或其他方式对其直接和间接利益的描述，包含在最终委托书声明第60页开始的题为“某些人在合并和分拆中的利益”的章节中（可在此处获取）。

其董事或高管持有的公司证券与2024 10-K中规定的金额相比的任何变化已反映在向美国证券交易委员会提交的表格4中的以下受益所有权声明中：表格4由Kelly Deck提交，公司于2024年3月6日、2024年三月12日、2024年3月15日、20243月22日、20244年3月28日和2024年5月8日提交；表格4，由Brendan Eckelman提交，公司于2024年3月12日和2024年三月15日提交。截至2024年5月10日，上述“参与者”“实益拥有”（在1934年《证券交易法》第13d-3条的含义范围内）不到1%的公司普通股股份，每股面值0.0001美元。

当向美国证券交易委员会提交与拟议收购相关的最终委托书时，有关潜在参与者身份及其直接或间接利益（通过证券持有或其他方式）的其他信息将包含在该委托书中。这些文件（如有）可从美国证券交易委员会网站www.SEC.gov和公司网站www.SEC.gov.免费获取https://www.inhibrx.com.

投资者和媒体联系人：Kelly Deck，首席财务官〔email protected〕858-795-4260

SOURCE Inhibrx，股份有限公司。